Chemical formula: C₁₂H₂₀N₂O₃S Molecular mass: 272.364 g/mol PubChem compound: 5253
D,l-sotalol is a non-selective hydrophilic β-adrenergic receptor blocking agent, devoid of intrinsic sympathomimetic activity or membrane stabilizing activity. Sotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C07AA07 | Sotalol | C Cardiovascular system → C07 Beta blocking agents → C07A Beta blocking agents → C07AA Beta blocking agents, non-selective |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| SOTALOL Tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Sotalol is an active ingredient of these brands:
United States (US)Australia (AU)Croatia (HR)
Cyprus (CY)Estonia (EE)
Finland (FI)
France (FR)
Ireland (IE)
Japan (JP)
Netherlands (NL)
New Zealand (NZ)
Singapore (SG)
South Africa (ZA)
Spain (ES)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
